Study on the Surface Acoustic Wave Sensor with Self-Assembly Imprinted Film of Calixarene Derivatives to Detect Organophosphorus Compounds

The molecularly imprinted technology and the self-assembly technique were used together on the calixarene surface acoustic wave (SAW) chemical sensors to detect organophosphorus compounds. 25-(thioalkyl-alkoxy)-p-tertbutylcalix[4] arene with self-assembled monolayer character was the sensitive coating of the sensors. The sensors had a special response to organophosphorus compounds and the response frequency shift of this sensor to organophosphorus compounds in 0.1 mg/m3 was 350 Hz. The response frequency increased linearly with the increase of the concentration of DMMP in the range from 0.1 to 0.6 mg/m3. The possible explanation of the interaction between the coatings and organophosphorus compounds was discussed.

Gonadotropin treatment for male partial congenital hypogonadotropic hypogonadism in Chinese patients

Partial congenital hypogonadotropic hypogonadism(PCHH)is caused by an insufficiency in,but not a complete lack of,gonadotropin secretion.This leads to reduced testosterone production,mild testicular enlargement,and partial pubertal development.No studies have shown the productivity of spermatogenesis in patients with PCHH.We compared the outcomes of gonadotropin-induced spermatogenesis between patients with PCHH and those with complete congenital hypogonadotropic hypogonadism(CCHH).This retrospective study included 587 patients with CHH who were treated in Peking Union Medical College Hospital(Beijing,China)from January 2008 to September 2016.A total of 465 cases were excluded from data analysis for testosterone or gonadotropin-releasing hormone treatment,cryptorchidism,poor compliance,or incomplete medical data.We defined male patients with PCHH as those with a testicular volume of≥4 ml and patients with a testicular volume of<4 ml as CCHH.A total of 122 compliant,noncryptorchid patients with PCHH or CCHH received combined human chorionic gonadotropin and human menopausal gonadotropin and were monitored for 24 months.Testicular size,serum luteinizing hormone levels,follicle-stimulating hormone levels,serum total testosterone levels,and sperm count were recorded at each visit.After gonadotropin therapy,patients with PCHH had a higher spermatogenesis rate(92.3%)than did patients with CCHH(74.7%).During 24-month combined gonadotropin treatment,the PCHH group took significantly less time to begin producing sperm compared with the CCHH group(median time:11.7 vs 17.8 months,P<0.05).In conclusion,after combined gonadotropin treatment,patients with PCHH have a higher spermatogenesis success rate and sperm concentrations and require shorter treatment periods for sperm production.